Why Is VerifyMe Stock (VRME) Up 80% Today?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 31 2025
0mins
Should l Buy VRME?
Source: TipRanks
Stock Surge: VerifyMe (VRME) stock surged 82.16% in pre-market trading after its subsidiary, PeriShip Global, secured a deal with UPS for access to promotional services and improved logistics management through API development.
Analyst Outlook: Wall Street analysts have given VerifyMe a consensus rating of Moderate Buy, with an average price target of $1.38, indicating a potential upside of 101.11% despite the stock's significant year-to-date decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRME
Wall Street analysts forecast VRME stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.995
Low
1.50
Averages
1.50
High
1.50
Current: 0.995
Low
1.50
Averages
1.50
High
1.50
About VRME
VerifyMe, Inc provides specialized logistics for time and temperature sensitive products, as well as brand protection and enhancement solutions. Its segments include Precision Logistics and Authentication. Its Precision Logistics segment includes the operations of its subsidiary, PeriShip Global, LLC. Its Precision Logistics segment provides service for sensitive parcel management driven by a software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, sort volumes, and traffic, delivered to customers via a secure portal. The Precision Logistics segment includes bundled services, such as PeriTrack, Service Center, Pre-Transit Service, Post-Delivery, and Weather/Traffic Service. The Authentication segment specializes in anti-counterfeit and brand protection. Its information technology (IT) platform provides real-time information and analysis for a range of markets, including the perishable healthcare and food industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VerifyMe and Open World Sign Merger Agreement to Enhance Digital Asset Infrastructure
- Merger Agreement: VerifyMe (VRME) has signed a merger agreement with blockchain infrastructure firm Open World, aiming to become a leading provider in digital asset and real-world asset tokenization, which is expected to significantly enhance market competitiveness.
- Platform Focus: The combined platform will concentrate on token listings, regulated digital asset infrastructure, and institutional-grade real-world asset tokenization across multiple jurisdictions, likely providing clients with more comprehensive services and solutions.
- Listing Plans: Upon completion of the merger, the new company is expected to list on Nasdaq under a new ticker symbol, further enhancing its market visibility and investor confidence.
- Shareholder Approval and Stock Reaction: Both companies' boards have unanimously approved the merger agreement, with VerifyMe terminating its at-the-market equity program; VRME shares rose 21% in premarket trading, indicating positive market sentiment towards the merger.
See More
OPEN WORLD AND VERIFYME FINALIZE MERGER AGREEMENT
Open World and Verify Me: The collaboration between Open World and Verify Me aims to enhance digital identity verification processes.
Definitive Merger Agreement: A definitive merger agreement has been established, indicating a strategic partnership to leverage each company's strengths in technology and services.
See More
VerifyMe Enters Strategic Merger Agreement with Open World
- Merger Intent Announcement: VerifyMe has signed a letter of intent for a strategic merger with Open World, with the expectation that Open World shareholders will own approximately 90% of the combined company, while VerifyMe shareholders will hold about 10%, significantly altering the market positions of both companies.
- Board Power Shift: Post-merger, Open World will have the right to appoint and replace certain members of the combined company's Board of Directors, which will enable it to dominate decision-making in the new entity and enhance its market influence.
- Special Cash Dividend Opportunity: VerifyMe is expected to pay a one-time cash dividend to its shareholders prior to the merger, equal to the amount of cash on its balance sheet exceeding $1 million, providing additional financial returns to shareholders and boosting their confidence.
- Stock Performance Surge: Following the announcement, VerifyMe's stock price surged by 59.29% to $1.07, indicating a positive market reaction to the merger prospects and potentially attracting more investor interest in the company's future growth potential.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
GH Research Plc Receives FDA Lift on Clinical Hold, Stock Rises 34.5%
- FDA Approval: The U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) on Monday, enabling the company to proceed with its clinical trials, which is expected to accelerate product development and enhance market competitiveness.
- Positive Market Reaction: Following the announcement, GH Research's stock surged 34.5% to $17.80, reflecting investor optimism about the company's future potential and likely attracting more investor interest in its subsequent developments.
- Industry Impact: This FDA approval not only brings direct capital inflow to GH Research but may also encourage other biotech firms to expedite their clinical trial processes, thereby fostering innovation and growth across the industry.
- Increased Investor Confidence: With the clinical hold lifted, GH Research is poised to accelerate its product launch timeline in the coming months, further boosting investor confidence and enhancing the company's market position in the biopharmaceutical sector.
See More
VerifyMe, Inc. Reports Increased Losses in Q3
Third Quarter Loss: VerifyMe, Inc. reported a loss of -$3.36 million for the third quarter, compared to a loss of -$2.42 million in the same period last year.
Earnings Per Share: The earnings per share (EPS) for the quarter was -$0.26, slightly worse than -$0.23 from the previous year.
Revenue Decline: The company's revenue decreased by 7.5%, totaling $5.03 million, down from $5.44 million in the prior year.
Earnings Overview: Key figures for VerifyMe, Inc. include a loss of -$3.36 million, an EPS of -$0.26, and revenue of $5.03 million for the quarter.
See More
VerifyMe and Open World Sign Merger Agreement to Enhance Digital Asset Infrastructure
- Merger Agreement: VerifyMe (VRME) has signed a merger agreement with blockchain infrastructure firm Open World, aiming to become a leading provider in digital asset and real-world asset tokenization, which is expected to significantly enhance market competitiveness.
- Platform Focus: The combined platform will concentrate on token listings, regulated digital asset infrastructure, and institutional-grade real-world asset tokenization across multiple jurisdictions, likely providing clients with more comprehensive services and solutions.
- Listing Plans: Upon completion of the merger, the new company is expected to list on Nasdaq under a new ticker symbol, further enhancing its market visibility and investor confidence.
- Shareholder Approval and Stock Reaction: Both companies' boards have unanimously approved the merger agreement, with VerifyMe terminating its at-the-market equity program; VRME shares rose 21% in premarket trading, indicating positive market sentiment towards the merger.
See More
OPEN WORLD AND VERIFYME FINALIZE MERGER AGREEMENT
Open World and Verify Me: The collaboration between Open World and Verify Me aims to enhance digital identity verification processes.
Definitive Merger Agreement: A definitive merger agreement has been established, indicating a strategic partnership to leverage each company's strengths in technology and services.
See More
VerifyMe Enters Strategic Merger Agreement with Open World
- Merger Intent Announcement: VerifyMe has signed a letter of intent for a strategic merger with Open World, with the expectation that Open World shareholders will own approximately 90% of the combined company, while VerifyMe shareholders will hold about 10%, significantly altering the market positions of both companies.
- Board Power Shift: Post-merger, Open World will have the right to appoint and replace certain members of the combined company's Board of Directors, which will enable it to dominate decision-making in the new entity and enhance its market influence.
- Special Cash Dividend Opportunity: VerifyMe is expected to pay a one-time cash dividend to its shareholders prior to the merger, equal to the amount of cash on its balance sheet exceeding $1 million, providing additional financial returns to shareholders and boosting their confidence.
- Stock Performance Surge: Following the announcement, VerifyMe's stock price surged by 59.29% to $1.07, indicating a positive market reaction to the merger prospects and potentially attracting more investor interest in the company's future growth potential.
See More
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
- Stock Surge: Momentus Inc. shares soared 57% to $8.98 following the announcement of an additive-manufactured fuel tank, indicating strong market confidence in its aerospace service potential.
- Flight Testing Plans: The fuel tank is scheduled for flight testing aboard the Vigoride-7 orbital service vehicle, which not only enhances the company's technological capabilities but also opens new revenue streams for future commercial launches.
- FDA Clearance: GH Research PLC shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application, marking a significant breakthrough in the company's development process that could accelerate product commercialization.
- Market Volatility: Despite a generally positive market, Zenas Biopharma Inc. shares plummeted 57% due to results from the INDIGO trial, reflecting the high-risk nature of the biopharmaceutical sector, necessitating cautious investment evaluations.
See More
GH Research Plc Receives FDA Lift on Clinical Hold, Stock Rises 34.5%
- FDA Approval: The U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) on Monday, enabling the company to proceed with its clinical trials, which is expected to accelerate product development and enhance market competitiveness.
- Positive Market Reaction: Following the announcement, GH Research's stock surged 34.5% to $17.80, reflecting investor optimism about the company's future potential and likely attracting more investor interest in its subsequent developments.
- Industry Impact: This FDA approval not only brings direct capital inflow to GH Research but may also encourage other biotech firms to expedite their clinical trial processes, thereby fostering innovation and growth across the industry.
- Increased Investor Confidence: With the clinical hold lifted, GH Research is poised to accelerate its product launch timeline in the coming months, further boosting investor confidence and enhancing the company's market position in the biopharmaceutical sector.
See More
VerifyMe, Inc. Reports Increased Losses in Q3
Third Quarter Loss: VerifyMe, Inc. reported a loss of -$3.36 million for the third quarter, compared to a loss of -$2.42 million in the same period last year.
Earnings Per Share: The earnings per share (EPS) for the quarter was -$0.26, slightly worse than -$0.23 from the previous year.
Revenue Decline: The company's revenue decreased by 7.5%, totaling $5.03 million, down from $5.44 million in the prior year.
Earnings Overview: Key figures for VerifyMe, Inc. include a loss of -$3.36 million, an EPS of -$0.26, and revenue of $5.03 million for the quarter.
See More
